

Children's Hospital




C Booth, MBBS, PhD¹; J Sevilla, MD, PhD²; GR Rao, MD, JD³; M Chitty Lopez, MD³; E Almarza, PhD^{3,4,5}; D Terrazas, RN⁶; J Zubicaray MD, PhD²; K Chetty, MBBS¹; G O'Toole¹; J Xu-Bayford¹; E Nicoletti, MD³; A Fernandes, PhD⁶; C Kuo, MD⁶; S de Oliveira, MD⁶; TB Moore, MD⁶; G Choi, BS³; M Zeini, PhD^{4,5}; AJ Thrasher, MBBS, PhD¹; J Bueren, PhD^{4,5}; JD Schwartz, MD³; DB Kohn, MD⁶


Abstract # 3460

¹UCL Great Ormond Street Institute of Child Health, London, UK, ²Fundación Biomédica en Red de Enfermedades Raras (CIBERER-ISCIII), Madrid, Spain, ³Rocket Pharmaceuticals, Inc., Cranbury, NJ, ⁴Centro de Investigaciones Energéticas Medioambientales y Tecnológicas (CIEMAT) and Centro de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), Madrid, Spain, ⁶University of California, Los Angeles, Los Angeles, CA

Introduction

- ITGB2 gene mutations affect the common chain (CD18) of the beta2-integrin family and prevent functional CD18/CD11 heterodimer expression on leukocyte cell surfaces – essential for cell adhesion and subsequent tissue migration.
- Severe leukocyte adhesion deficiency-I LAD-I is characterized by recurrent and ultimately fatal disseminated infections.
- <u>Current Treatment Option</u>: Allogeneic hematopoietic stem cell transplantation (HSCT) – limited by donor availability, infections, frequent GvHD and graft failure.
- Patients suffer from recurrent infections; fatal in majority
- 60–75% patients with severe LAD-I: death **prior to age 2**
- o >50% patients with moderate LAD-I: death prior age 40





End Points

Primary Outcomes

Phase 1:

• Safety and preliminary efficacy

Phase 2:

- Survival: Proportion of patients alive at age 2 and at least 1-year post infusion (and not requiring allogeneic HSCT)
- Safety

Secondary Outcomes

- Incidence of severe infections, hospitalizations, and prolonged hospitalizations
- % of patients with neutrophil CD18 expression at least 10% of normal
- % of patients with neutrophil VCN of ≥0.1 at 6 months post-RP-L201 infusion
- Improvement / normalization of leukocytosis
- Resolution (partial or complete) of underlying skin rash or periodontal abnormalities

Key Eligibility

- Severe LAD-I; CD18 expression <2% PMNs, or CD11a/b <2% with documented ITGB2 mutation
- Age ≥3 months
- At least one prior significant bacterial of fungal infection

Takeda: Honoraria; Consultancy; GSK: Honoraria; Takeda: Honoraria; Tak There are no relationships to disclose. E Nicoletti: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. There are no relationships to disclose. I Xu-Bayford: There are no relationships to disclose. E Nicoletti: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. There are no relationships to disclose. I Xu-Bayford: There are no relationships to disclose. I Xu-Bayford: There are no relationships to disclose. I Xu-Bayford: There are no relationships to disclose. E Nicoletti: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. There are no relationships to disclose. I Xu-Bayford: There are no relationships to disc C Kuo: There are no relationships to disclose. De Oliveira: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. M Zeini: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. C Mesa-Núñez: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. Schwartz: Rocket Pharmaceuticals, Inc.: Employment, Equity Ownership. M Zeini: Rocket Pharmaceuticals, Inc.: Employment, Equity Pharmaceuticals, Inc.: Employment, Equity Ownership. Kohn: Consultancy and Scientific Advisory Board Member: Allogene Therapeutics, Pluto Therapeutics, ImmunoVec, MyoGeneBio.

Lentiviral-Mediated Ex-Vivo Gene Therapy for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I): **Interim Results from an ongoing Phase 1/2 Study**

Severe: <2% CD18+PMN

Patient Demographics and	Investigational	Drod
Patient Demographics and	a investigational	Prod

Patient	Sex	Age at enrollment	Investigational Product VCN
L201-003-1001	F	9 years	3.8
L201-003-1004	F	3 years	2.5
L201-003-2005	F	3 years	1.8
L201-003-2006	Μ	7 months	2.9
L201-003-2007	Μ	3 months	3.6
L201-004-2008	Μ	5 months	3.8
L201-004-2009	Μ	3 years	2.0
L201-002-2010	F	4 years	3.5
L201-003-2011	F	2 years	3.8

Spontaneous LAD-I Related Skin Rash Resolution and Restoration of Wound Repair Capabilities after RP-L201

1: Spontaneous resolution of abdominal lesion 201-003-1

Age (Months)




interim results are presented from the ongoing clinical study










RP-L201 Study Design



- follow-up
- (SAEs)
- <u>Safety profile</u> of RP-L201 appears favorable
- Initial integration site analysis (ISA) indicates highly polyclonal patterns without evidence of dominant integrations in proximity to oncogenic *loci*
- Efficacy evident in 9 out of 9 patients, including 7 patients with ≥12 months of follow-up
- Sustained >10% CD18 polymorphonuclear cell (PMN) expression (Range: 87.4%–19.6%, Median: 56.3%) with concomitant durable >0.1 VCN integration across the cohort
- 100% overall survival (OS), including 100% OS one-year post-RP-L201 and to 2 years of age
- **Significant reduction** in all hospitalizations, infection and inflammatory-related hospitalizations, prolonged hospitalizations, and severe infections
- Evidence of spontaneous resolution of LAD-I-related skin rash and restoration of wound repair capabilities





GREAT ORMOND STREET INSTITUTE OF CHILD HEALTH

Conclusions

All (9 out of 9) severe LAD-I patients have successfully received RP-L201; currently with 3–24 months of

• Infusion has been well tolerated; no investigational product- (RP-L201) related serious adverse events